CA3226268A1 - M6pr cell surface receptor binding compounds and conjugates - Google Patents
M6pr cell surface receptor binding compounds and conjugates Download PDFInfo
- Publication number
- CA3226268A1 CA3226268A1 CA3226268A CA3226268A CA3226268A1 CA 3226268 A1 CA3226268 A1 CA 3226268A1 CA 3226268 A CA3226268 A CA 3226268A CA 3226268 A CA3226268 A CA 3226268A CA 3226268 A1 CA3226268 A1 CA 3226268A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- conjugate
- formula
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221915P | 2021-07-14 | 2021-07-14 | |
| US63/221,915 | 2021-07-14 | ||
| PCT/US2022/037196 WO2023288015A1 (en) | 2021-07-14 | 2022-07-14 | M6pr cell surface receptor binding compounds and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226268A1 true CA3226268A1 (en) | 2023-01-19 |
Family
ID=82786881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226268A Pending CA3226268A1 (en) | 2021-07-14 | 2022-07-14 | M6pr cell surface receptor binding compounds and conjugates |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335544A1 (https=) |
| EP (1) | EP4370156A1 (https=) |
| JP (1) | JP2024524613A (https=) |
| CN (1) | CN117915956A (https=) |
| AU (1) | AU2022310346A1 (https=) |
| CA (1) | CA3226268A1 (https=) |
| WO (1) | WO2023288015A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| JP2026503462A (ja) | 2023-01-18 | 2026-01-29 | ライシア セラピューティクス， インコーポレイテッド | 自己抗体の分解のためのリソソーム標的化二官能性分子 |
| CN120835794A (zh) * | 2023-01-18 | 2025-10-24 | 利西亚治疗公司 | M6pr结合化合物和缀合物 |
| CN120882430A (zh) | 2023-01-18 | 2025-10-31 | 利西亚治疗公司 | 循环溶酶体靶向抗体缀合物 |
| WO2024182772A2 (en) * | 2023-03-02 | 2024-09-06 | Avilar Therapeutics, Inc. | Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins |
| FR3149188A1 (fr) * | 2023-05-31 | 2024-12-06 | Nanomedsyn | Pro-ligands, conjugués comprenant lesdits pro-ligands et leurs utilisations pour des applications thérapeutiques |
| CN121548590A (zh) * | 2023-07-25 | 2026-02-17 | 深圳湾实验室 | 一种多特异性结合蛋白及其应用 |
| WO2026015664A1 (en) | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| CA3205824A1 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| FR3041345B1 (fr) * | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
| AU2019404061A1 (en) | 2018-12-19 | 2021-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
| US20230051872A1 (en) | 2019-03-22 | 2023-02-16 | Reflexion Pharmaceuticals, Inc. | Multivalent D-Peptidic Compounds for Target Proteins |
| KR20220044612A (ko) | 2019-03-22 | 2022-04-08 | 리플렉시온 파마슈티컬스, 인크. | Vegf에 대한 d-펩티드성 화합물 |
| US20230158155A1 (en) | 2020-01-10 | 2023-05-25 | Lycia Therapeutics, Inc. | Cell Surface Receptor Binding Compounds and Conjugates |
| EP4171658A4 (en) * | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
| EP4171659A4 (en) * | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | BIFUNCTIONAL BRIDGE COMPOSITIONS FOR VIRAL TRANSDUCTION |
-
2022
- 2022-07-14 AU AU2022310346A patent/AU2022310346A1/en active Pending
- 2022-07-14 CA CA3226268A patent/CA3226268A1/en active Pending
- 2022-07-14 JP JP2024501118A patent/JP2024524613A/ja active Pending
- 2022-07-14 CN CN202280060559.6A patent/CN117915956A/zh active Pending
- 2022-07-14 US US18/578,293 patent/US20240335544A1/en active Pending
- 2022-07-14 EP EP22750970.0A patent/EP4370156A1/en active Pending
- 2022-07-14 WO PCT/US2022/037196 patent/WO2023288015A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024524613A (ja) | 2024-07-05 |
| US20240335544A1 (en) | 2024-10-10 |
| CN117915956A (zh) | 2024-04-19 |
| EP4370156A1 (en) | 2024-05-22 |
| WO2023288015A1 (en) | 2023-01-19 |
| AU2022310346A1 (en) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3226268A1 (en) | M6pr cell surface receptor binding compounds and conjugates | |
| CA3167272A1 (en) | Cell surface receptor binding compounds and conjugates | |
| CA3226269A1 (en) | Asgpr cell surface receptor binding compounds and conjugates | |
| AU2017359043B2 (en) | Steroids and protein-conjugates thereof | |
| CN112004557B (zh) | 类固醇类化合物及其抗体偶联物 | |
| AU2018269568B2 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| KR102877468B1 (ko) | 흔적이 없는 링커 및 이의 단백질-접합체 | |
| AU2018270784B2 (en) | Cyclodextrin protein drug conjugates | |
| CA3080857A1 (en) | Hydrophilic linkers for antibody drug conjugates | |
| CA3198788A1 (en) | Camptothecine antibody-drug conjugates and methods of use thereof | |
| KR20210106467A (ko) | 튜불리신 및 단백질-튜불리신 접합체 | |
| CA3185601A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2024155748A1 (en) | M6pr binding compounds and conjugates | |
| TW202519267A (zh) | Siglec配體、接合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250520 |